Obituaries
PGe
PG Store
Archives
Classifieds
Classified
Events
Jobs
Real Estate
Legal Notices
Pets
MENU
SUBSCRIBE
LOGIN
REGISTER
LOG OUT
MY PROFILE
Home
News
Local
Sports
Opinion
A&E
Life
Business
Contact Us
NEWSLETTERS
MENU
ACCOUNT
Subscribe
Login
Register
Log out
My Profile
Subscriber Services
Search
SECTIONS
HOME
Homepage
This Just In
Chats
Weather
Traffic
Event Guide
PG Store
PGe
Video
Photos
The Digs
RSS Feeds
NEWS
News Home
COVID-19
World
Nation
State
Obituaries
News Obituaries
Politics
Education
Portfolio
Science
Health & Wellness
Environment
Aging Edge
Transportation
Faith & Religion
Crimes & Courts
Social Services
LOCAL
Local Home
Region
City
North
East
West
South
Washington
Westmoreland
The Neighborhood
Obituaries
Classifieds
Legal Notices
Real Estate
SPORTS
Sports Home
Steelers
Penguins
Pirates
Sports Columns
Gene Collier
Ron Cook
Joe Starkey
Paul Zeise
High School Sports
College Sports
Pitt
Penn State
WVU
NCAA
NFL
MLB
NBA
NHL
North Shore Drive Podcast
OPINION
Opinion Home
Editorials
Letters
Op-Ed Columns
PG Columnists
Insight
A&E
A&E Home
Celebrities
Movies
TV & Radio
Music
Concert Listings
Theatre & Dance
Art & Architecture
Books
Events
LIFE
Life Home
Food
Buying Here
Homes & Gardens
Style & Fashion
Travel
Restaurants
Seen
goodness
Random Acts of Kindness
Pets
Beer Me
Outdoors
Holidays
BUSINESS
Business Home
Your Money
Wheels
Workzone
Business Health
Tech News
Building PGH
Powersource
Business / Law
Top Workplaces
Business of Pittsburgh
Consumer Alerts
OTHER
PGe
NEWSLETTERS
PG STORE
ARCHIVES
CLASSIFIEDS
OBITUARIES
JOBS
LEGAL NOTICES
REAL ESTATE
CLASSIFIEDS
EVENTS
PETS
CONTACT US / FAQ
CONTACT US
ADVERTISING
CAREER OPPORTUNITIES
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Articles published by ProMIS Neurosciences Inc.
ProMIS Neurosciences Announces Second Quarter 2024 Financial Results and Recent Highlights
August 08, 2024
From
ProMIS Neurosciences Inc.
Via
GlobeNewswire
Tickers
PMN
ProMIS Neurosciences Announces Data on the Pathogenic Role of Toxic Misfolded SOD1 Aggregates in ALS Published in Acta Neuropathologica and Open Biology
August 06, 2024
From
ProMIS Neurosciences Inc.
Via
GlobeNewswire
Tickers
PMN
ProMIS Neurosciences to Participate in BTIG Virtual Biotechnology Conference 2024
August 01, 2024
From
ProMIS Neurosciences Inc.
Via
GlobeNewswire
Tickers
PMN
ProMIS Neurosciences Showcases Novel Vaccine Approach for Maximal Targeting of Toxic Amyloid-Beta Oligomers at the 2024 Alzheimer’s Association International Conference
July 30, 2024
From
ProMIS Neurosciences Inc.
Via
GlobeNewswire
Tickers
PMN
ProMIS Neurosciences Reports Positive Top-Line Data from its Phase 1a Alzheimer's Trial
July 26, 2024
From
ProMIS Neurosciences Inc.
Via
GlobeNewswire
Tickers
PMN
ProMIS Neurosciences Announces Up to $122.7 Million Private Placement Financing
July 26, 2024
From
ProMIS Neurosciences Inc.
Via
GlobeNewswire
Tickers
PMN
ProMIS Neurosciences Announces First Quarter 2024 Financial Results and Recent Highlights
May 14, 2024
From
ProMIS Neurosciences Inc.
Via
GlobeNewswire
Tickers
PMN
TSX:PMN
ProMIS Neurosciences Publishes Study Highlighting Oligomer Selectivity and Benefit of Amyloid-Beta-Directed Antibodies
April 30, 2024
From
ProMIS Neurosciences Inc.
Via
GlobeNewswire
Tickers
PMN
TSX:PMN
ProMIS Neurosciences Publishes in the Journal of Biological Chemistry on the Interaction Between Pathogenic Proteins as a Treatment Target for ALS
April 09, 2024
From
ProMIS Neurosciences Inc.
Via
GlobeNewswire
Tickers
PMN
TSX:PMN
ProMIS Neurosciences to Present in Upcoming Investor Conferences in April
April 04, 2024
From
ProMIS Neurosciences Inc.
Via
GlobeNewswire
Tickers
PMN
TSX:PMN
ProMIS Neurosciences Announces Full Year 2023 Financial Results and Recent Highlights
April 01, 2024
From
ProMIS Neurosciences Inc.
Via
GlobeNewswire
Tickers
PMN
TSX:PMN
ProMIS Neurosciences Strengthens Global Intellectual Property Portfolio
March 11, 2024
From
ProMIS Neurosciences Inc.
Via
GlobeNewswire
Tickers
PMN
TSX:PMN
ProMIS Neurosciences to Present at the 2024 BIO CEO & Investor Conference
February 22, 2024
From
ProMIS Neurosciences Inc.
Via
GlobeNewswire
Tickers
PMN
TSX:PMN
ProMIS Neurosciences Achieves Milestone in Development of Therapeutic Alpha-Synuclein Vaccine
January 22, 2024
From
ProMIS Neurosciences Inc.
Via
GlobeNewswire
Tickers
PMN
TSX:PMN
ProMIS Neurosciences Issues Letter to Shareholders
January 08, 2024
From
ProMIS Neurosciences Inc.
Via
GlobeNewswire
Tickers
PMN
TSX:PMN
ProMIS Neurosciences, Inc. Announces Leadership Transition
January 03, 2024
From
ProMIS Neurosciences Inc.
Via
GlobeNewswire
Tickers
PMN
TSX:PMN
ProMIS Neurosciences Announces Publication on Novel Target for ALS
December 20, 2023
From
ProMIS Neurosciences Inc.
Via
GlobeNewswire
Tickers
PMN
TSX:PMN
ProMIS Neurosciences Doses First Subjects in Phase 1a Clinical Trial of PMN310 to Treat Alzheimer’s Disease
November 20, 2023
From
ProMIS Neurosciences Inc.
Via
GlobeNewswire
Tickers
PMN
TSX:PMN
ProMIS Neurosciences Announces Third Quarter 2023 Financial Results and Recent Highlights
November 14, 2023
From
ProMIS Neurosciences Inc.
Via
GlobeNewswire
Tickers
PMN
TSX:PMN
ProMIS Neurosciences Closes $20.4 Million Private Placement Financing
September 08, 2023
From
ProMIS Neurosciences Inc.
Via
GlobeNewswire
Tickers
PMN
TSX:PMN
ProMIS Neurosciences to Present at the H.C. Wainwright 25th Annual Global Investment Conference
September 06, 2023
From
ProMIS Neurosciences Inc.
Via
GlobeNewswire
Tickers
PMN
TSX:PMN
ProMIS Neurosciences Announces $20.4 Million Private Placement Financing
August 21, 2023
From
ProMIS Neurosciences Inc.
Via
GlobeNewswire
Tickers
PMN
TSX:PMN
ProMIS Neurosciences Announces Second Quarter 2023 Financial Results and Recent Highlights
August 14, 2023
From
ProMIS Neurosciences Inc.
Via
GlobeNewswire
Tickers
PMN
TSX:PMN
ProMIS Showcases Preclinical Data at the Alzheimer’s Association International Conference 2023 on Computationally-Derived Antibody and Vaccine from Alzheimer’s Pipeline
July 17, 2023
From
ProMIS Neurosciences Inc.
Via
GlobeNewswire
Tickers
PMN
TSX:PMN
ProMIS Announces Completion of Continuance
July 14, 2023
From
ProMIS Neurosciences Inc.
Via
GlobeNewswire
Tickers
PMN
TSX:PMN
ProMIS Neurosciences to Consolidate Trading on the Nasdaq Exchange
July 10, 2023
From
ProMIS Neurosciences Inc.
Via
GlobeNewswire
Tickers
PMN
TSX:PMN
ProMIS Neurosciences Holds Annual Meeting of Shareholders All Resolutions Approved
June 30, 2023
From
ProMIS Neurosciences Inc.
Via
GlobeNewswire
Tickers
PMN
TSX:PMN
CORRECTION: Updated URL to Access ProMIS Annual Meeting of Shareholders on June 29, 2023 at 9:30am Eastern Time
June 29, 2023
From
ProMIS Neurosciences Inc.
Via
GlobeNewswire
Tickers
PMN
TSX:PMN
ProMIS Neurosciences Announces First Quarter 2023 Financial Results and Recent Highlights
May 15, 2023
From
ProMIS Neurosciences Inc.
Via
GlobeNewswire
Tickers
PMN
TSX:PMN
ProMIS Neurosciences Announces FDA Clearance of Investigational New Drug (IND) Application for PMN310 in Alzheimer’s Disease
May 08, 2023
From
ProMIS Neurosciences Inc.
Via
GlobeNewswire
Tickers
PMN
TSX:PMN
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.
TOP
Email a Story
Your e-mail:
Friends e-mail:
Submit